Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Equities researchers at Wedbush increased their Q2 2018 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Thursday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.52) per share for the quarter, up from their previous forecast of ($1.84). Wedbush currently has a “Outperform” rating and a $62.00 target price on the stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q3 2018 earnings at ($1.78) EPS, Q4 2018 earnings at ($1.78) EPS, FY2018 earnings at ($5.96) EPS, FY2019 earnings at ($6.32) EPS, FY2020 earnings at ($4.27) EPS and FY2021 earnings at $0.07 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period in the prior year, the business earned ($1.46) EPS.

TRADEMARK VIOLATION WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/19/wedbush-comments-on-ultragenyx-pharmaceutical-inc-s-q2-2018-earnings-rare.html.

Several other brokerages have also recently commented on RARE. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Sanford C. Bernstein began coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, July 27th. They set a “market perform” rating and a $72.00 price target on the stock. Canaccord Genuity set a $98.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, July 28th. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus price target of $71.65.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 52.99 on Monday. The company’s market capitalization is $2.25 billion. The firm’s 50-day moving average price is $56.92 and its 200 day moving average price is $63.21. Ultragenyx Pharmaceutical has a 12-month low of $49.56 and a 12-month high of $91.35.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of the firm’s stock in a transaction on Monday, August 28th. The shares were purchased at an average price of $52.52 per share, for a total transaction of $393,900.00. Following the transaction, the chief executive officer now directly owns 430,569 shares in the company, valued at approximately $22,613,483.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 9.20% of the company’s stock.

Several large investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. grew its position in shares of Ultragenyx Pharmaceutical by 3.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 115 shares in the last quarter. Prudential Financial Inc. grew its position in shares of Ultragenyx Pharmaceutical by 5.8% during the 1st quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 200 shares in the last quarter. Amalgamated Bank grew its position in shares of Ultragenyx Pharmaceutical by 4.6% during the 1st quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 202 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Ultragenyx Pharmaceutical by 8.0% during the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. Finally, Aperio Group LLC grew its position in shares of Ultragenyx Pharmaceutical by 8.4% during the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after purchasing an additional 299 shares in the last quarter. Hedge funds and other institutional investors own 96.07% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.